Progenics Pharmaceuticals (NASDAQ:PGNX) completed enrollment for its Phase 3 study testing the diagnostic performance and clinical impact of 18F-DCFPyL (PyL) in men with recurrent prostate cancer. PyL, a small molecule...
Brookline Capital Markets initiated coverage of Progenics Pharmaceuticals (NASDAQ:PGNX) with a “buy” rating and $10 price target. The stock closed at $5.25 on July 29. “We expect that Progenics is well poised to ramp up...